Volume 34, Issue 3 pp. 505-525
REVIEW

Mangiferin: Possible uses in the prevention and treatment of mixed osteoarthritic pain

Bárbara B. Garrido-Suárez

Corresponding Author

Bárbara B. Garrido-Suárez

Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba

Correspondence

Bárbara B. Garrido-Suárez, Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Ave. 26 No. 1605, Nuevo Vedado, Havana, Cuba.

Email: [email protected]

Gabino Garrido, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Antofagasta, Chile.

Email: [email protected]

Search for more papers by this author
Gabino Garrido

Corresponding Author

Gabino Garrido

Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Antofagasta, Chile

Correspondence

Bárbara B. Garrido-Suárez, Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Ave. 26 No. 1605, Nuevo Vedado, Havana, Cuba.

Email: [email protected]

Gabino Garrido, Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Antofagasta, Chile.

Email: [email protected]

Search for more papers by this author
Octavio Piñeros

Octavio Piñeros

Departamento de Investigaciones, Universidad de Santiago de Cali, Cali, Colombia

Search for more papers by this author
René Delgado-Hernández

René Delgado-Hernández

Centro de Estudio para las Investigaciones y Evaluaciones Biológicas, Instituto de Farmacia y Alimentos, Universidad de La Habana, Havana, Cuba

Search for more papers by this author
First published: 22 November 2019
Citations: 11

Abstract

Osteoarthritis (OA) pain has been proposed to be a mixed pain state, because in some patients, central nervous system factors are superimposed upon the more traditional peripheral factors. In addition, a considerable amount of preclinical and clinical evidence has shown that, accompanying the central neuroplasticity changes and partially driven by a peripheral nociceptive input, a real neuropathic component occurs that are particularly linked to disease severity and progression. Hence, innovative strategies targeting neuroprotection and particularly neuroinflammation to prevent and treat OA pain could be introduced. Mangiferin (MG) is a glucosylxanthone that is broadly distributed in higher plants, such as Mangifera indica L. Previous studies have documented its analgesic, anti-inflammatory, antioxidant, neuroprotective, and immunomodulatory properties. In this paper, we propose its potential utility as a multitargeted compound for mixed OA pain, even in the context of multimodal pharmacotherapy. This hypothesis is supported by three main aspects: the cumulus of preclinical evidence around this xanthone, some preliminary clinical results using formulations containing MG in clinical musculoskeletal or neuropathic pain, and by speculations regarding its possible mechanism of action according to recent advances in OA pain knowledge.

CONFLICT OF INTEREST

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.